Company news from the 03/13/07 news brief

Share this article:
A New Jersey jury on Monday ordered Merck to pay $47.5 million in damages after finding the drugmaker’s Vioxx was responsible for a plaintiff’s heart attack. Merck said it intends to appeal the verdict and the damages. European database and software solutions provider Cegedim has announced plans to acquire sales, marketing solution provider Dendrite in a deal worth approximately $751 million. Dorland Global Corporation launched a new Web site at dorland.com, featuring a blog by Dorland Global co-founder, Harry Sweeney, a longtime advertising agency veteran who also serves as chair of the Coalition for Healthcare Communications. The blog will feature guest diarists, including agency executives, clients and colleagues in the healthcare communications industry, according to a news release. Publicis Groupe has acquired sales, marketing and Prescription Drug Marketing Act (PDMA) compliance firm Pharmagistics. Financial terms of the deal were not disclosed. Pharmagistics, based in Somerset, NJ, offers four key services including distribution of samples and literature to pharmaceutical sales forces, direct marketing solutions (direct-to-practitioner), PDMA compliant sample accountability services and specialty logistical services. Pharmagistics will remain a separate unit with its own identity operating within Publicis Groupe's Publicis Healthcare Communications Group, a Publicis Groupe news release said.
Share this article:

Email Newsletters

More in News

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...

Bayer drug gets orphan label

Bayer drug gets orphan label

The FDA designation is for an experimental, inhaled form of ciprofloxacin intended to treat a rare lung condition.

Lilly's cancer drug ramu granted gastric indication

Lilly's cancer drug ramu granted gastric indication

Ramucirumab received FDA approval today in advanced gastric cancer, a nod that could translate into $600 million in peak sales.